• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Sweden·Healthcare·MCOV-B.ST
Share

Medicover AB Stocks

SEK 276Last Updated 23.10.2026

Issuer Rating

5/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

SEK 4.23B

SEK 276
Key Takeaways

Risk factor

Resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Medicover AB (publ), established in Stockholm, Sweden in 1995, operates as a comprehensive provider of healthcare and diagnostic services throughout a dozen countries, including Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. The company's operations are distinctly categorized into two segments: Healthcare Services and Diagnostic Services. Within its Diagnostic Services arm, Medicover performs an extensive array of laboratory analyses. These span various specialties, encompassing tests for allergies and autoimmune conditions, infectious agents (bacteriology, parasitology, microbiology), biochemical and immunological markers, blood grouping and transfusion requirements, tumor detection, clinical chemistry, cellular and tissue pathology (cytology, haematology, histopathology), human genetics, hygiene, molecular biology, and pharmacological/toxicological screenings. This substantial diagnostic infrastructure includes 97 clinical laboratories, 733 blood collection points, and 26 specialized clinics, operational across 10 of its countries of presence. Complementing this, the Healthcare Services division features a broad network comprising 117 medical clinics, 20 fertility centers, 52 dental practices, 25 hospitals, and 25 fitness facilities. Medicover caters to a diverse clientele, serving corporate clients, private individuals, direct patients, and public sector payers.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of MCOV-B.ST is 297 and suggests 7.61% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommend

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

26.10.2026 23:40

Buyers of the foldable iPhone have complained about screen damage. How does this affect the stock price?

26.10.2026 23:02

One of Wall Street's leading optimists has withdrawn his "bullish" recommendation on the stock

26.10.2026 22:15

Revolut has begun offering consumer loans in the U.K. What does this mean for the company?

26.10.2026 21:31

Tesla shares surged: Barclays advised buying them ahead of the merger with SpaceX

26.10.2026 21:09

"We Decided Not to Delay": What Analysts Are Saying About Anthropic's IPO Prospectus

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026